Sunrun Inc vs Summit Therapeutics Inc — how do they compare? Sunrun Inc trades at $10.19 (market cap $2.42B), while Summit Therapeutics Inc trades at $15.37 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 5× Sunrun Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Sunrun Inc nearer its low. Which is the better fit depends on your goals.
| RUN | SMMT | |
|---|---|---|
Market Cap | $2.42B | $12.06B |
Sector | Technology | Health |
52-Week High | $21.41 | $26.98 |
52-Week Low | $9.38 | $12.55 |
Enterprise Value | $16.93B | $11.39B |
Signals from Pluang's Aura AI — not financial advice
Sunrun (RUN) trades at $10.19, up 3.24% today, but faces bearish technical signals despite strong earnings beats in recent quarters. The company shows solid valuation metrics with P/E of 6.82 and P/S of 0.78, though cash flow remains negative from operations. Recent news highlights mixed sentiment with Q2 earnings beating expectations but guidance cuts weighing on investor confidence.
The outlook remains cautious with analyst consensus bullish (62% buy ratings) and a $14.38 price target suggesting 41% upside potential. Key risks include negative operating cash flow, high debt levels, and competitive pressures in the solar industry. The stock offers value opportunity but requires careful monitoring of cash generation improvements.
No Aura AI signal available yet.
Trailing returns across standard periods
Sunrun Inc. is one of the largest residential solar, battery storage, and energy services companies in the United States. The company provides solar panel installations, battery backup systems, and energy management solutions to homeowners. Sunrun primarily uses a solar-as-a-service model, offering customers solar leases and power purchase agreements (PPAs), which allow homeowners to adopt solar energy with little to no upfront cost. The company's mission is to create a planet run by the sun.
Read more on RUN →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →